Indan Journal of Medical Research Indan Journal of Medical Research Indan Journal of Medical Research Indan Journal of Medical Research
  Home About us Editorial board Search Ahead of print Current issue Archives Submit article Instructions Subscribe Contacts Login  
  Home Print this page Email this page Small font sizeDefault font sizeIncrease font size Users Online: 1242       

   Table of Contents      
SYSTEMATIC REVIEW
Year : 2018  |  Volume : 148  |  Issue : 1  |  Page : 56-76

Relationship between type of smokeless tobacco & risk of cancer: A systematic review


1 Division of Cytopathology, ICMR-National Institute of Cancer Prevention & Research, Noida, India
2 School of Preventive Oncology, Patna, India
3 WHO FCTC Global Knowledge Hub for Smokeless Tobacco, ICMR-National Institute of Cancer Prevention & Research, Noida, India

Date of Submission22-Dec-2017
Date of Web Publication25-Sep-2018

Correspondence Address:
Dr Sanjay Gupta
Division of Cytopathology, ICMR-National Institute of Cancer Prevention & Research, I-7, Sector-39, Noida 201 301, Uttar Pradesh
India
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/ijmr.IJMR_2023_17

Rights and Permissions
   Abstract 

Background & objectives: Causative linkages of smokeless tobacco (SLT) use with oral potentially malignant disorders and cancers of oral cavity, oesophagus and pancreas have been reported. Published meta-analyses have provided pooled risk estimates for major cancers caused by SLT, both on global and regional levels. This systematic review was aimed at summarizing the available studies on occurrence and mortality risk of common cancers due to various SLT products.
Methods: PubMed and Google Scholar databases were systematically searched from 1985 till January 2018 for observational studies on SLT and cancer. The included studies were evaluated and data were extracted and reviewed.
Results: The review included 80 studies providing 121 risk estimates for various cancers. Majority of the studies from South-East Asian Region (SEAR) and Eastern Mediterranean Region (EMR) showed a significant positive association of SLT use with oral [odds ratio (OR) ranging from 1.48 to 27.4] and oesophageal cancers (OR between 2.06 and 12.8), while studies from European Region (EUR) reported a positive association with pancreatic cancer (OR between 1.6 and 2.1). Cancer-related mortality was evaluated in a few reports with higher risk of mortality for lung (OR between 2.0 and 9.1), cervical (OR 2.0) and prostate (OR 2.1) cancers. A wide variation was noted in the association of various cancers and specific SLT products based on their nature, methods of use and inherent toxicity. The majority of chewing tobacco products displayed higher risk for oral and oesophageal cancers while the same was not observed for snus.
Interpretation & conclusions: This review emphasizes on the significantly positive association of SLT use with oral and oesophageal cancers in SEAR and EMR and pancreatic cancer in EUR. Mortality estimates for SLT-associated cancers need further analysis. Risk analysis for cancers of other sites in SLT users also requires multicentric well-designed studies.

Keywords: Cancer - mortality - occurrence - oesophagus - oral - pancreas - pharynx - smokeless tobacco


How to cite this article:
Gupta S, Gupta R, Sinha DN, Mehrotra R. Relationship between type of smokeless tobacco & risk of cancer: A systematic review. Indian J Med Res 2018;148:56-76

How to cite this URL:
Gupta S, Gupta R, Sinha DN, Mehrotra R. Relationship between type of smokeless tobacco & risk of cancer: A systematic review. Indian J Med Res [serial online] 2018 [cited 2020 May 28];148:56-76. Available from: http://www.ijmr.org.in/text.asp?2018/148/1/56/242221

Smokeless tobacco (SLT) consumed orally or nasally has been in use for as long as other forms of tobacco. Research studies conducted over years have shown linkage of SLT use with oral potentially malignant disorders and cancers of oral cavity, oesophagus and pancreas along with possible contributory role in cardiovascular disease, hypertension, peptic ulcer and foetal morbidity and mortality[1].

SLT products are known to contain more than 30 carcinogens, including tobacco-specific N-nitrosamines (TSNAs), nitrite, nitrate and heavy metals such as nickel, cadmium and chromium[2]. The levels of these carcinogens vary widely among the SLT products consumed in different countries. The additives used in these products leading to changes in toxicity and associated health risks also differ in various geographic regions. This hinders the comparability of results of various studies evaluating the health effects of SLT use[3].

A conceptual model of SLT-associated carcinogenesis postulates that carcinogens present in SLT products are ingested and processed, leading to metabolic activation of carcinogens. The carcinogens cause formation of DNA adducts and subsequent mutations in K-ras, p53 and other genes, leading to uncontrolled cell growth. Other changes, including chronic local inflammation, oxidative stress and formation of reactive oxygen species, may also contribute to tumour promotion[4]. Mechanisms such as activation of Akt and protein kinase A lead to reduced apoptosis and increased angiogenesis and cellular transformation. Apart from TSNAs, other compounds present in SLT products such as polycyclic aromatic hydrocarbons and areca nut may also contribute to causation of cancer in SLT users. Epigenetic pathways, such as promoter methylation of tumour-suppressor genes leading to unregulated proliferation, are also speculated to be involved in SLT-related carcinogenesis[5].

Summary risk estimates of cancer occurrence have shown a higher risk of oral cancer [risk ratio (RR) 3.43, 95% confidence interval (CI) 2.26-5.19], pharyngeal cancer (2.23, 95% CI 1.55-3.20) and oesophageal cancer (2.17, 95% CI 1.70-2.78) in SLT users[6]. However, regional variation in this risk has also been demonstrated. Risk for mortality due to cancers of upper aerodigestive tract (UADT), stomach and uterine cervix has also been shown to be significantly higher with SLT use[7]. This systematic review was undertaken to summarize the available studies (categorized into WHO-defined Regions) on cancer occurrence as well as mortality risk in users of SLT products.


   Material & Methods Top


A systematic literature search was conducted in PubMed and Google Scholar databases for articles on SLT-associated cancers published since 1985 till January 2018 using the search terms ‘smokeless tobacco,’ ‘chewing tobacco,’ ‘snus,’ ‘snuff,’ ‘khaini,’ ‘gutka,’ ‘toombak,’ ‘shammah,’ ‘tuibur’ and ‘cancer’ or ‘neoplasm.’ The PRISMA guidelines were followed[8]. The flow chart shows the search strategy used [Figure 1]. Cross-references of all included articles were also examined for additional studies.
Figure 1: Flow chart showing search strategy for studies on association of SLT with cancer. OPMD, oral potentially malignant diseases.

Click here to view


Inclusion criteria: (i) Articles published in English language or published in other languages with summary having detailed results available in English; (ii) Case-control or cohort studies including any age group and either or both gender and total sample size of at least 100; (iii) Exposure variable: SLT in one of its various forms; (iv) Outcome: Cancer of oral cavity, nasal cavity, pharynx, larynx, oesophagus, stomach, lung, uterine cervix, breast, prostate, urinary bladder, kidney, penis, brain, skin, colon and rectum; leukaemia/ lymphoma, multiple myeloma; sarcoma; and (v) Risk estimate: Estimates for combined exposure or individual SLT products were extracted. Gender-wise estimates were noted, where available.

Exclusion criteria: Case series, case reports, letters or reviews, reports of only precancerous lesions, duplicate data, and reports of chewable products without tobacco were excluded.

Data extraction: Each article was subjected to quality assessment by two authors. Data regarding type of study, location, sample size, publication year, exposure variable, outcome definition and risk estimates with 95 per cent CIs were extracted for risk of occurrence and mortality and compared. Any disparities were resolved by deliberations and final decision was reached by mutual consensus. Risk estimates were also recorded for different SLT products, wherever available.


   Results Top


The initial search yielded 4470 articles, of which 80 studies providing 121 risk estimates for various cancers were included in this review. Of these, 47 were conducted in WHO South-East Asian Region (SEAR, 46 in India, 1 in Indonesia), 12 in European Region (EUR), 11 in American Region (AMR), eight in Eastern Mediterranean Region (EMR) and two in African Region (AFR). No studies were retrieved from Western Pacific Region (WPR).

Smokeless tobacco (SLT) and cancer occurrence risk

Oral cancer: Risk of occurrence of oral cancer has been extensively assessed for the association with SLT; 33 studies (22 from SEAR, 5 EMR, 3 EUR, 2 AFR and 1 AMR) were retrieved in the selected time period [Table 1]. Majority of these studies have been case-control (28 of 33) while only five (three from SEAR and two from EUR) were cohort studies.
Table 1: Characteristics of studies on risk of occurrence of site-specific cancers in smokeless tobacco (SLT) users included in the review

Click here to view


Cohort studies: Of the five cohort studies evaluating risk of oral cancer in SLT users, all three from SEAR[9],[10],[11] showed a significant positive association with SLT intake while both studies from EUR[12],[13] did not show this positive association. Of the four studies mentioning SLT product, two studies evaluating risk of oral cancer in snus users did not find an increased risk of occurrence of oral cancer[12],[13] while both the studies evaluating risk with tobacco chewing reported higher risk of oral cancer in chewers[10],[11]. Four of these five studies adjusted for smoking as a confounding factor.

Case-control studies: Nineteen (19) case-control studies were retrieved from SEAR, of which 16 reported a significant positive association with the use of SLT products[17],[18],[19],[24],[25],[26],[27],[29],[30],[31],[32],[33],[37],[39],[40],[41] while the remaining three did not concur with this association[22],[23],[28]. The single studies from EUR[35] and AMR[38] did not detect any significant positive association of oral cancer with SLT use. All five studies from EMR[15],[16],[20],[21],[34] and two from AFR[14],[36] demonstrated significantly higher risk of oral cancer in SLT users.

Seven studies gave separate estimates for males and females, and found significantly higher risk of oral cancer both in male and female SLT users[14],[25],[27],[32],[39],[40],[41]. Some studies demonstrated a higher risk of cancer in female users [odds ratio (OR) ranging between 3.2 and 45.89] compared to males in the same study (OR ranging from 2.7 to 9.33).

There were 30 estimates mentioning the type of SLT product - 22 on chewing products, five on snuff, two on toombak and one on naswar. One study evaluated the risk of oral cancer with naswar as well as the use of paan with tobacco. Of the 22 studies assessing risk of oral cancer with chewing tobacco products, 15 specified the product including gutka, betel quid, paan with tobacco, zarda, khaini and mishri. Fourteen studies reported a significant positive association between oral cancer and SLT product while one study did not find similar association[22]. The remaining seven studies mentioned only tobacco chewing in the exposure variable without specifying the product type; of these, four demonstrated significantly higher risk of oral cancer in chewers while three did not find any similar association. Both the studies including toombak users and two estimates for risk of oral cancer in naswar users reported significant positive association[14],[15],[34],[36]. Snuff was evaluated in five studies; two found significantly higher risk of oral cancer in users[40],[41] while three studies did not report similar risk[18],[35],[38]. Of the 28 case-control studies, eight did not adjust for smoking as a confounding variable.

Cancer of pharynx (excluding nasopharynx): Six studies [Table 1] were found for risk of occurrence of pharyngeal cancer (all from SEAR[17],[30],[33],[42],[43],[44]) in SLT users. There was one cohort study[42] while the rest five were case-control in design[17],[30],[33],[43],[44]. All these studies evaluated this association with chewing tobacco. Three studies did not report significant association with SLT use[17],[33],[42] while two showed positive association[30],[44]. In the study by Sapkota et al[43], positive association was found only with zarda while the same was not true for khaini, mawa and gutka. Six of seven studies were adjusted for smoking.

Oesophageal cancer: Risk of oesophageal cancer in SLT users has been evaluated in 15 studies (11 from SEAR[9],[30],[46],[47],[48],[49],[51],[52],[54],[55],[56], three EUR[13],[45],[53] and one EMR[50]). Only three were cohort[9],[13],[45] while the rest 12 were case-control studies[30],[46],[47],[48],[49],[50],[51],[52],[53],[54],[55],[56]. Of the cohort studies, one report each from SEAR and EUR showed significant positive association between SLT use and oesophageal cancer[9],[45]. The third study from EUR did not find an increased risk of oesophageal cancer in snus users[13].

Nine of ten case-control studies from SEAR demonstrated a higher risk of oesophageal cancer in SLT users[30],[46],[47],[48],[49],[51],[52],[54],[56] while one study did not report any similar risk[55]. The study from EMR reported a significant positive association between SLT use and oesophageal cancer[50] while the report from EUR[53] did not find a positive association. Ten studies evaluated chewing tobacco - six specifying the product including zarda, khaini, gutka, betel quid, tobacco alone or paan with tobacco. Of these six studies, five found significantly higher risk of oesophageal cancer in tobacco users while one did not report similar association with gutka though this study found positive association of nass chewing and oesophageal cancer[48]. On the other hand, three studies evaluated snuff; two of these (from SEAR[49] and EMR[50]) revealed significantly higher risk of oesophageal cancer in snuff users while the study from EUR[53] did not report similarly higher risk of cancer. Smoking was adjusted as a confounding variable in 14 studies while alcohol was adjusted in only nine studies [Table 1].

Gastric cancer: Of the nine studies included, four were conducted in SEAR[58],[59],[60],[62], four in EUR[13],[45],[53],[61] and one in EMR[57], as depicted in [Table 1]. Of these, two were cohort studies[13],[45] while seven were case-control in design[53],[57],[58],[59],[61],[62]. Of the cohort studies, the report by Zendehdel et al[45] showed significant positive association of cancer of non-cardia part of stomach with SLT use while the same was not found for cancers in the cardia region. The other cohort study did not find increased risk of gastric cancer in snus users[13]. Among the case-control studies, report from EMR (shammah users)[57] and those from SEAR evaluating the effect of tuibur intake[58],[59] reported a significantly higher risk of gastric cancer. However, the studies including users of chewing tobacco (shammah, paan with tobacco, betel quid) or snuff did not reveal significantly positive association with gastric cancer[53],[60],[61],[62].

Colorectal cancer: Three studies (one pooled cohort[63] one cohort[64], and one case-control[65]) were retrieved evaluating risk of colorectal cancer in SLT users. Of these, only one study with pooled cohort reported a significantly higher risk of rectal cancer in snus users. However, risk of colon cancer was not found to be higher in SLT users in any of the studies [Table 1].

Pancreatic cancer: Five studies (two EUR[12],[13], two AMR[66],[67] and one SEAR[9]) have assessed the risk of risk of occurrence of pancreatic cancer in SLT users [Table 1]. Three studies were cohort[9],[12],[13] while two were case-control reports[66],[67]. Two cohort studies, both from EUR[12],[13], reported significant positive association between snus use and pancreatic cancer. The third cohort study as well as both case-control studies did not find a similar association[9],[66],[67]. All the five studies were adjusted for smoking as a confounding factor.

Respiratory cancer: Two studies evaluated association of SLT with laryngeal cancer (both SEAR[42],[43]) and both studies (subjects consuming chewing tobacco) reported lack of significant positive association of SLT with cancer of larynx [Table 1].

Lung cancer was evaluated in three cohort[9],[12],[13] and four case-control studies[33],[68],[69],[70]. One of the cohort (SLT type not specified[9]) and one of case-control studies (assessing chewing tobacco[68]) demonstrated significant positive association of lung cancer with SLT use. The other cohort and case-control studies failed to detect similar association between SLT use and lung cancer [Table 1]. All the seven studies were adjusted smoking as a confounding variable.

Other cancers: Other neoplasias including breast cancer[71],[72], cervical cancer[73], lymphoma[74], genitourinary tumours[13],[75],[76] liver[9], and others[77],[78],[79] have also been evaluated for their association with SLT use with variable results in sporadic studies [Table 2].
Table 2: Studies on association of smokeless tobacco (SLT) and risk of occurrence of cancer of other body sites

Click here to view


Smokeless tobacco (SLT) and cancer mortality

Eight studies providing 19 individual estimates for mortality due to various cancers were retrieved for this review [Table 3][80],[81],[82],[83],[84],[85],[86],[87]. Of these, seven studies provided estimates for digestive tract cancers, three for respiratory, two for combined oral and pharyngeal cancers, two for genitourinary and one each for pharyngeal, upper aero-digestive tract (UADT), breast and cervical cancers. Significantly higher risk of mortality was found for lung (OR ranging from 2.0[81] to 9.1[86]), cervical (OR 2.0 and 2.2 for urban and rural females, respectively[84]), prostate (OR 2.1, 95% CI 1.1-4.1[87]) and UADT (OR between 1.9 and 3.8[84]). Due to small number of studies on individual cancer and mortality risk, product-specific assessment was not attempted.
Table 3: Characteristics of studies on cancer-related mortality and smokeless tobacco (SLT) use included in the review

Click here to view



   Discussion Top


SLT products have a worldwide presence in various forms - chewing tobacco in the USA, snuff (snus) in Sweden and mixture of chewing tobacco with other ingredients in developing countries[1]. Reviews in the mid-1980s as well as the US Surgeon General Report in 1986 concluded that SLT products had negative health implications[88]. Recent analyses have demonstrated significant morbidity and mortality related to SLT use. One study estimated that globally, 1.7 million disability-adjusted life years (DALYs) were lost and 62,283 deaths were attributed to SLT-associated cancers based on estimated burden of disease figures available for 113 countries[6]. Another meta-analysis calculated 3.6 million DALYs and 101,004 deaths due to cancers associated with SLT use[89]. A monograph on SLT and Public Health in India reported that 90 per cent of oral and pharyngeal cancers were caused by tobacco in some form and 50 per cent of these are attributable to SLT[90]. However, the multitude and heterogeneity of products have raised doubts on these associations. Due to significant differences in composition, production and usage practices of SLT, the levels of most important carcinogens such as TSNA, vary widely across different SLT products[91].

A systematic review of health effects of SLT published in 2003 reported significant risk of oral cancers due to betel quid and tobacco chewing in India while studies from the US and Scandinavian countries did not report significant positive association[1]. Since this review, there have been a few region-specific or cancer-specific systematic reviews and meta-analyses on SLT[7],[89],[92]. However, review on association of various cancers with SLT products in a global perspective has not been conducted recently.

Risk of cancer occurrence in SLT users

The present review re-emphasizes the strong association between SLT use and occurrence of oral cancer with risk estimates ranging from 1.48 (1.03-2.13)[9] to 27.4 (10.0-74.7)[15], especially for studies originating from SEAR. Occasional studies from SEAR did not find significant positive association of oral cancer with SLT use[22],[23],[28]. This could partly be attributed to the fewer number of controls in one study[22]. Studies from EUR, fewer in number compared to those from SEAR, have not found a significant positive association between SLT use and cancer[12],[13],[35]. An earlier meta-analysis showed overall 34 per cent higher risk of oral cancer in SLT users although regional variation was evident[6]. Sinha et al[7], in their meta-analysis of Indian studies, gave a risk estimate of 5.67 (3.83-8.40) for oral cancer in SLT users [Table 4].
Table 4: Results of published meta-analyses on association of smokeless tobacco use with cancer occurrence and mortality

Click here to view


A review of studies from the USA found significantly higher risk of oral cancer with chewing tobacco as well as snuff[93]. Meta-analysis of studies from South Asia and Pacific concluded increased risk of oral cancer in tobacco chewers (7.46, 5.86-9.50) although need for conducting studies focussing on different types of tobacco and eliciting dose–response relationship was emphasized[94]. An Indian study has demonstrated a linear dose–response association of oral cancer and chewing tobacco[95]. This regional variation in risk estimates can partly be explained by the chemical composition of SLT products, especially levels of TSNAs, and their usage practices. The SEAR has the maximum diversity in SLT products as well as their usage methods, varying from chewing tobacco alone to a mixture of tobacco with ingredients such as betel quid and/ or areca nut (both recognized as carcinogens), lime and other such products[96]. Some products are sucked, gargled/sipped or used as a dentrifice [Table 5][97]. A review of toxicology of SLT products available in India highlighted the disturbingly high levels of TSNAs in the most popular brands of SLT products such as khaini, zarda and mishri[99]. Various authors have also detected TSNAs in the saliva of tobacco chewers[100],[101]. In addition, mutagenic effects of extracts of SLT products have also been demonstrated[102]. Formation of micronucleus as a genotoxic effect has been reported in exfoliated buccal epithelial cells from tobacco chewers[103]. A few studies in the present review reported a higher risk of cancer in female SLT users (OR ranging between 3.2 and 45.89)[14],[32] compared to male users in the same study (OR ranging from 2.7 to 9.33)[27],[39]. A previous meta-analysis of studies from India also showed a significantly higher risk of oral cancer in female users (pooled OR 12.09, 95% CI 9.49-15.25) compared to males (5.16, 95% CI 4.49-5.94)[7]. This difference may be attributed to the behavioural differences in the usage of SLT products between males and females.
Table 5: Commonly used smokeless tobacco (SLT) products described in this review - Composition, usage practice and toxicology

Click here to view


Results on association of SLT use and pharyngeal cancer have been conflicting as can be seen from [Table 1]. However, earlier meta-analyses have shown 22 and 30 per cent higher risk of occurrence of pharyngeal cancer in SLT users[6],[7]. Unlike oral cancer where tobacco is the most important aetiologic agent, pharyngeal cancer, especially oropharyngeal, is causatively linked to human papillomavirus (HPV)[104]. Synergistic effect of smoking and HPV16 positivity on the causation of head and neck cancer have been demonstrated[104] though the same has not been proved for SLT products as yet.

Another significant positive association highlighted is that of oesophageal cancer and SLT products. Majority of studies from SEAR, the single study from EMR and one of two reports from EUR demonstrated positive association of oesophageal cancer with SLT use. A previous global review of SLT-related diseases reported an overall 20 per cent higher risk of oesophageal cancer in SLT users with maximum risk detected in the analysis of studies from EMR and SEAR[6]. Similar positive association was reported in a meta-analysis of Indian studies[7].

Studies on gastric cancer have reported conflicting results with reports from EUR not finding positive association while majority of SEAR and EMR studies demonstrating higher risk of gastric cancer with SLT use. However, a previous meta-analysis of Indian studies did not find significant positive association between gastric cancer and SLT use (1.31, 95% CI 0.92-1.87)[7]. The association of pancreatic cancer with SLT use has been demonstrated in Scandinavian reports though studies from America have not supported this association[12],[13]. The Scandinavian studies have shown this increased risk in SLT users after adjustment for smoking and alcohol use[13] or in never-smoking stratum[12]. Animal model experiments have shown the occurrence of pancreatic adenocarcinoma in rats exposed to TSNAs or their metabolites as well as effect of TSNAs on point mutations in the RAS gene that is implicated in pancreatic carcinogenesis[105],[106]. TSNAs have also been documented in human pancreatic juice at higher concentration in smokers compared to non-smokers[107]. However, the available evidence lacks detailed information regarding the chemical composition of the SLT products consumed in different Regions. Since the toxicity of SLT products differs according to their composition and manufacturing practices, effect of these products in causation of various cancers has been debatable in the studies from different Regions.

The role of SLT use in occurrence of cancers such as colorectal, lung, breast and cervix has not been established beyond doubt as yet and needs further exploration by well-controlled studies.

Cancer-related mortality and SLT use

In comparison with the number of studies evaluating cancer occurrence in SLT users, research into cancer-related mortality with SLT use has been scarce. In the present review, only 19 individual risk estimates were retrieved for mortality of various cancers in SLT users. A previous meta-analysis of SLT-attributable mortality showed significantly higher risk of deaths due to UADT, gastric and cervical cancers in SLT users. Regional variation was noted for mortality outcome of UADT cancer with significant positive association in estimates from SEAR while the same was not true for those from AMR[89]. However, a limitation of this analysis was the small number of estimates included for each cancer. In addition, mortality estimates were not available from all Regions.

A cohort study from south India on effect of tobacco chewing on cancer mortality did not find significant positive association (1.07, 95% CI 0.94-1.22) after adjustment for age, gender, socio-economic status and dietary variables. However, age-wise evaluation showed detrimental effects on cancer mortality in the middle age group, 40-59 yr (1.26, 95% CI 1.03-1.55)[108].

Due to paucity of studies evaluating cancer-related mortality in SLT users, conclusive opinion on cancer-specific, Region-wise or product-related mortality risk for various cancers is currently not possible. Exploring this aspect would need well-designed studies with appropriate adjustment for confounding factors.

Strengths and limitations

The strengths of this review include the wide and comprehensive range of cancers included, thorough literature review and global coverage to the widest extent possible. Cancer sites not considered by previous reviews and meta-analyses were also included in the present review.

However, there were certain limitations also. Many of the observational studies included inadequate descriptions of SLT use as ‘ever or never’ without defining the type of SLT product or estimating the dose-response relationship. Second, biochemical validation of SLT use was not conducted in majority of the studies. Self-reporting of SLT use is fraught with recall bias as well as intentional hiding of facts by the subjects. Such bias can lead to misclassification of subjects as cases or controls, leading to confounding results. A significant limitation of this review was the lack of uniformity of case definition in accordance with the International Classification of Diseases (ICD-10) system, especially for oral cancers. Many studies included in the review failed to mention the case definition criteria. The definition of various outcomes was also not uniform across studies. This was of special concern in the evaluation of studies on mortality since the data from developing countries were usually lacking in the completeness and certification of cause of death. In such a scenario, confounding by other causes of death in a cancer patient could not be excluded with confidence. Absence of studies from WPR limited the evaluation of SLT and cancer association in this Region. From AFR, only two studies evaluating role of toombak in risk of oral cancer were retrieved. Other cancer sites were not examined in AFR for the association with SLT products. Another limitation pertained to countries like India with wide inter-State variations in SLT products. Studies reported from such countries are not distributed uniformly through the country; however, the results are considered to represent the country as a whole.


   Conclusion & recommendations for the future Top


The present review highlights the significant positive association of SLT use with risk of oral and oesophageal cancer in SEAR and EMR. Higher risk of pancreatic cancer in SLT users has been emphasized in studies from EUR. Association of SLT products with cancers of other sites and with cancer-related mortality is still an unresolved issue that requires robust studies from across the globe.

Although association of SLT and oral cancer is well accepted especially for SEAR, further studies with adequate power and control of confounding factors are required from other Regions, as well as for other cancers to establish their association with SLT. The studies should specifically address the product-specific association to enable clear policy decisions and also to refute the claims of tobacco industry regarding relative safety of SLT products as an alternative to quitting for smokers. To address the latter issue, studies also need to include a category of ‘switchers’ in their long-term follow up to obtain real estimates of adverse health consequences of SLT use compared to smoking.

Financial support & sponsorship: None.

Conflicts of Interest: None.



 
   References Top

1.
Critchley JA, Unal B. Health effects associated with smokeless tobacco: A systematic review. Thorax 2003; 58 : 435-43.  Back to cited text no. 1
    
2.
IARC Working Group on the Evaluation of Carcinogenic Risks to Humans. Smokeless tobacco and some tobacco-specific N-nitrosamines. IARC Monogr Eval Carcinog Risks Hum 2007; 89 : 1-592.  Back to cited text no. 2
    
3.
Boffetta P, Hecht S, Gray N, Gupta P, Straif K. Smokeless tobacco and cancer. Lancet Oncol 2008; 9 : 667-75.  Back to cited text no. 3
    
4.
Hecht SS. Tobacco carcinogenesis. In: Schwab M, editor. Encyclopedia of cancer. Berlin, Heidelberg: Springer Berlin Heidelberg; 2011. p. 3717-9.  Back to cited text no. 4
    
5.
Stanfill SB, Connolly GN, Zhang L, Jia LT, Henningfield JE, Richter P, et al. Global surveillance of oral tobacco products: Total nicotine, unionised nicotine and tobacco-specific N-nitrosamines. Tob Control 2011; 20 : e2.  Back to cited text no. 5
    
6.
Siddiqi K, Shah S, Abbas SM, Vidyasagaran A, Jawad M, Dogar O, et al. Global burden of disease due to smokeless tobacco consumption in adults: Analysis of data from 113 countries. BMC Med 2015; 13 : 194.  Back to cited text no. 6
    
7.
Sinha DN, Abdulkader RS, Gupta PC. Smokeless tobacco-associated cancers: A systematic review and meta-analysis of Indian studies. Int J Cancer 2016; 138 : 1368-79.  Back to cited text no. 7
    
8.
Moher D, Liberati A, Tetzlaff J, Altman DG; PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: The PRISMA statement. BMJ 2009; 339 : b2535.  Back to cited text no. 8
    
9.
Pednekar MS, Gupta PC, Yeole BB, Hébert JR. Association of tobacco habits, including bidi smoking, with overall and site-specific cancer incidence: Results from the Mumbai cohort study. Cancer Causes Control 2011; 22 : 859-68.  Back to cited text no. 9
    
10.
Jayalekshmi PA, Gangadharan P, Akiba S, Koriyama C, Nair RRK. Oral cavity cancer risk in relation to tobacco chewing and bidi smoking among men in Karunagappally, Kerala, India: Karunagappally cohort study. Cancer Sci 2011; 102 : 460-7.  Back to cited text no. 10
    
11.
Jayalekshmi PA, Gangadharan P, Akiba S, Nair RRK, Tsuji M, Rajan B, et al. Tobacco chewing and female oral cavity cancer risk in Karunagappally cohort, India. Br J Cancer 2009; 100 : 848-52.  Back to cited text no. 11
    
12.
Luo J, Ye W, Zendehdel K, Adami J, Adami HO, Boffetta P, et al. Oral use of Swedish moist snuff (snus) and risk for cancer of the mouth, lung, and pancreas in male construction workers: A retrospective cohort study. Lancet 2007; 369 : 2015-20.  Back to cited text no. 12
    
13.
Boffetta P, Aagnes B, Weiderpass E, Andersen A. Smokeless tobacco use and risk of cancer of the pancreas and other organs. Int J Cancer 2005; 114 : 992-5.  Back to cited text no. 13
    
14.
Hassanin AA, Idris AM. Attribution of oral cancer in the Sudan to toombak dipping. Transl Res Oral Oncol 2017; 2 : 2057178X1668572.  Back to cited text no. 14
    
15.
Khan Z, Dreger S, Shah SMH, Pohlabeln H, Khan S, Ullah Z, et al. Oral cancer via the bargain bin: The risk of oral cancer associated with a smokeless tobacco product (Naswar). PLoS One 2017; 12 : e0180445.  Back to cited text no. 15
    
16.
Awan KH, Hussain QA, Patil S, Maralingannavar M. Assessing the risk of oral cancer associated with gutka and other smokeless tobacco products: A case-control study. J Contemp Dent Pract 2016; 17 : 740-4.  Back to cited text no. 16
    
17.
Nair S, Datta S, Thiagarajan S, Chakrabarti S, Nair D, Chaturvedi P, et al. Squamous cell carcinoma of the upper aerodigestive tract in exclusive smokers, chewers, and those with no habits. Indian J Cancer 2016; 53 : 538-41.  Back to cited text no. 17
    
18.
Mahapatra S, Kamath R, Shetty BK, Binu VS. Risk of oral cancer associated with gutka and other tobacco products: A hospital-based case-control study. J Cancer Res Ther 2015; 11 : 199-203.  Back to cited text no. 18
    
19.
Kadashetti V, Chaudhary M, Patil S, Gawande M, Shivakumar KM, Patil S, et al. Analysis of various risk factors affecting potentially malignant disorders and oral cancer patients of central India. J Cancer Res Ther 2015; 11 : 280-6.  Back to cited text no. 19
    
20.
Merchant AT, Pitiphat W. Total, direct, and indirect effects of paan on oral cancer. Cancer Causes Control 2015; 26 : 487-91.  Back to cited text no. 20
    
21.
Quadri MFA, Alharbi F, Bajonaid AMS, Moafa IHY, Sharwani AA, Alamir AHA, et al. Oral squamous cell carcinoma and associated risk factors in Jazan, Saudi Arabia: A hospital based case control study. Asian Pac J Cancer Prev 2015; 16 : 4335-8.  Back to cited text no. 21
    
22.
Krishna A, Singh RK, Singh S, Verma P, Pal US, Tiwari S, et al. Demographic risk factors, affected anatomical sites and clinicopathological profile for oral squamous cell carcinoma in a North Indian population. Asian Pac J Cancer Prev 2014; 15 : 6755-60.  Back to cited text no. 22
    
23.
Lakhanpal M, Yadav DS, Devi TR, Singh LC, Singh KJ, Latha SP, et al. Association of interleukin-1β -511 C/T polymorphism with tobacco-associated cancer in Northeast India: A study on oral and gastric cancer. Cancer Genet 2014; 207 : 1-1.  Back to cited text no. 23
    
24.
Amtha R, Razak IA, Basuki B, Roeslan BO, Gautama W, Puwanto DJ, et al. Tobacco (kretek) smoking, betel quid chewing and risk of oral cancer in a selected Jakarta population. Asian Pac J Cancer Prev 2014; 15 : 8673-8.  Back to cited text no. 24
    
25.
Ray JG, Ganguly M, Rao BS, Mukherjee S, Mahato B, Chaudhuri K, et al. Clinico-epidemiological profile of oral potentially malignant and malignant conditions among areca nut, tobacco and alcohol users in Eastern India: A hospital based study. J Oral Maxillofac Pathol 2013; 17 : 45-50.  Back to cited text no. 25
    
26.
Madani AH, Dikshit M, Bhaduri D. Risk for oral cancer associated to smoking, smokeless and oral dip products. Indian J Public Health 2012; 56 : 57-60.  Back to cited text no. 26
    
27.
Muwonge R, Ramadas K, Sankila R, Thara S, Thomas G, Vinoda J, et al. Role of tobacco smoking, chewing and alcohol drinking in the risk of oral cancer in Trivandrum, India: A nested case-control design using incident cancer cases. Oral Oncol 2008; 44 : 446-54.  Back to cited text no. 27
    
28.
Anantharaman D, Chaubal PM, Kannan S, Bhisey RA, Mahimkar MB. Susceptibility to oral cancer by genetic polymorphisms at CYP1A1, GSTM1 and GSTT1 loci among Indians: Tobacco exposure as a risk modulator. Carcinogenesis 2007; 28 : 1455-62.  Back to cited text no. 28
    
29.
Subapriya R, Thangavelu A, Mathavan B, Ramachandran CR, Nagini S. Assessment of risk factors for oral squamous cell carcinoma in Chidambaram, Southern India: A case-control study. Eur J Cancer Prev 2007; 16 : 251-6.  Back to cited text no. 29
    
30.
Znaor A, Brennan P, Gajalakshmi V, Mathew A, Shanta V, Varghese C, et al. Independent and combined effects of tobacco smoking, chewing and alcohol drinking on the risk of oral, pharyngeal and esophageal cancers in Indian men. Int J Cancer 2003; 105 : 681-6.  Back to cited text no. 30
    
31.
Buch SC, Notani PN, Bhisey RA. Polymorphism at GSTM1, GSTM3 and GSTT1 gene loci and susceptibility to oral cancer in an Indian population. Carcinogenesis 2002; 23 : 803-7.  Back to cited text no. 31
    
32.
Balaram P, Sridhar H, Rajkumar T, Vaccarella S, Herrero R, Nandakumar A, et al. Oral cancer in Southern India: The influence of smoking, drinking, paan-chewing and oral hygiene. Int J Cancer 2002; 98 : 440-5.  Back to cited text no. 32
    
33.
Dikshit RP, Kanhere S. Tobacco habits and risk of lung, oropharyngeal and oral cavity cancer: A population-based case-control study in Bhopal, India. Int J Epidemiol 2000; 29 : 609-14.  Back to cited text no. 33
    
34.
Merchant A, Husain SS, Hosain M, Fikree FF, Pitiphat W, Siddiqui AR, et al. Paan without tobacco: An independent risk factor for oral cancer. Int J Cancer 2000; 86 : 128-31.  Back to cited text no. 34
    
35.
Schildt EB, Eriksson M, Hardell L, Magnuson A. Oral snuff, smoking habits and alcohol consumption in relation to oral cancer in a Swedish case-control study. Int J Cancer 1998; 77 : 341-6.  Back to cited text no. 35
    
36.
Idris AM, Ahmed HM, Malik MO. Toombak dipping and cancer of the oral cavity in the sudan: A case-control study. Int J Cancer 1995; 63 : 477-80.  Back to cited text no. 36
    
37.
Rao DN, Ganesh B, Rao RS, Desai PB. Risk assessment of tobacco, alcohol and diet in oral cancer – A case-control study. Int J Cancer 1994; 58 : 469-73.  Back to cited text no. 37
    
38.
Mashberg A, Boffetta P, Winkelman R, Garfinkel L. Tobacco smoking, alcohol drinking, and cancer of the oral cavity and oropharynx among U.S. veterans. Cancer 1993; 72 : 1369-75.  Back to cited text no. 38
    
39.
Sankaranarayanan R, Duffy SW, Padmakumary G, Day NE, Krishan Nair M. Risk factors for cancer of the buccal and labial mucosa in Kerala, Southern India. J Epidemiol Community Health 1990; 44 : 286-92.  Back to cited text no. 39
    
40.
Nandakumar A, Thimmasetty KT, Sreeramareddy NM, Venugopal TC, Rajanna, Vinutha AT, et al. A population-based case-control investigation on cancers of the oral cavity in Bangalore, India. Br J Cancer 1990; 62 : 847-51.  Back to cited text no. 40
    
41.
Sankaranarayanan R, Duffy SW, Padmakumary G, Day NE, Padmanabhan TK. Tobacco chewing, alcohol and nasal snuff in cancer of the gingiva in Kerala, India. Br J Cancer 1989; 60 : 638-43.  Back to cited text no. 41
    
42.
Jayalekshmi PA, Nandakumar A, Akiba S, Gangadharan P, Koriyama C. Associations of tobacco use and alcohol drinking with laryngeal and hypopharyngeal cancer risks among men in Karunagappally, Kerala, India – Karunagappally cohort study. PLoS One 2013; 8 : e73716.  Back to cited text no. 42
    
43.
Sapkota A, Gajalakshmi V, Jetly DH, Roychowdhury S, Dikshit RP, Brennan P, et al. Smokeless tobacco and increased risk of hypopharyngeal and laryngeal cancers: A multicentric case-control study from India. Int J Cancer 2007; 121 : 1793-8.  Back to cited text no. 43
    
44.
Wasnik KS, Ughade SN, Zodpey SP, Ingole DL. Tobacco consumption practices and risk of oro-pharyngeal cancer: A case-control study in central India. Southeast Asian J Trop Med Public Health 1998; 29 : 827-34.  Back to cited text no. 44
    
45.
Zendehdel K, Nyrén O, Luo J, Dickman PW, Boffetta P, Englund A, et al. Risk of gastroesophageal cancer among smokers and users of Scandinavian moist snuff. Int J Cancer 2008; 122 : 1095-9.  Back to cited text no. 45
    
46.
Das M, Sharma SK, Sekhon GS, Saikia BJ, Mahanta J, Phukan RK, et al. Promoter methylation of MGMT gene in serum of patients with esophageal squamous cell carcinoma in North East India. Asian Pac J Cancer Prev 2014; 15 : 9955-60.  Back to cited text no. 46
    
47.
Talukdar FR, Ghosh SK, Laskar RS, Mondal R. Epigenetic, genetic and environmental interactions in esophageal squamous cell carcinoma from Northeast India. PLoS One 2013; 8 : e60996.  Back to cited text no. 47
    
48.
Dar NA, Bhat GA, Shah IA, Iqbal B, Makhdoomi MA, Nisar I, et al. Hookah smoking, nass chewing, and oesophageal squamous cell carcinoma in Kashmir, India. Br J Cancer 2012; 107 : 1618-23.  Back to cited text no. 48
    
49.
Sehgal S, Kaul S, Gupta BB, Dhar MK. Risk factors and survival analysis of the esophageal cancer in the population of Jammu, India. Indian J Cancer 2012; 49 : 245-50.  Back to cited text no. 49
    
50.
Akhtar S, Sheikh AA, Qureshi HU. Chewing areca nut, betel quid, oral snuff, cigarette smoking and the risk of oesophageal squamous-cell carcinoma in South Asians: A multicentre case-control study. Eur J Cancer 2012; 48 : 655-61.  Back to cited text no. 50
    
51.
Phukan RK, Ali MS, Chetia CK, Mahanta J. Betel nut and tobacco chewing; potential risk factors of cancer of oesophagus in Assam, India. Br J Cancer 2001; 85 : 661-7.  Back to cited text no. 51
    
52.
Nayar D, Kapil U, Joshi YK, Sundaram KR, Srivastava SP, Shukla NK, et al. Nutritional risk factors in esophageal cancer. J Assoc Physicians India 2000; 48 : 781-7.  Back to cited text no. 52
    
53.
Lagergren J, Bergström R, Lindgren A, Nyrén O. The role of tobacco, snuff and alcohol use in the aetiology of cancer of the oesophagus and gastric cardia. Int J Cancer 2000; 85 : 340-6.  Back to cited text no. 53
    
54.
Nandakumar A, Anantha N, Pattabhiraman V, Prabhakaran PS, Dhar M, Puttaswamy K, et al. Importance of anatomical subsite in correlating risk factors in cancer of the oesophagus – Report of a case – Control study. Br J Cancer 1996; 73 : 1306-11.  Back to cited text no. 54
    
55.
Sankaranarayanan R, Duffy SW, Padmakumary G, Nair SM, Day NE, Padmanabhan TK, et al. Risk factors for cancer of the oesophagus in Kerala, India. Int J Cancer 1991; 49 : 485-9.  Back to cited text no. 55
    
56.
Rao DN, Sanghvi LD, Desai PB. Epidemiology of esophageal cancer. Semin Surg Oncol 1989; 5 : 351-4.  Back to cited text no. 56
    
57.
Al-Qadasi FA, Shah SA, Ghazi HF. Tobacco chewing and risk of gastric cancer: A case-control study in Yemen. East Mediterr Health J 2017; 22 : 719-26.  Back to cited text no. 57
    
58.
Malakar M, Devi KR, Phukan RK, Kaur T, Deka M, Puia L, et al. P53 codon 72 polymorphism interactions with dietary and tobacco related habits and risk of stomach cancer in Mizoram, India. Asian Pac J Cancer Prev 2014;15 : 717-23.  Back to cited text no. 58
    
59.
Phukan RK, Zomawia E, Narain K, Hazarika NC, Mahanta J. Tobacco use and stomach cancer in Mizoram, India. Cancer Epidemiol Biomarkers Prev 2005; 14 : 1892-6.  Back to cited text no. 59
    
60.
Rao DN, Ganesh B, Dinshaw KA, Mohandas KM. A case-control study of stomach cancer in Mumbai, India. Int J Cancer 2002; 99 : 727-31.  Back to cited text no. 60
    
61.
Ye W, Ekström AM, Hansson LE, Bergström R, Nyrén O. Tobacco, alcohol and the risk of gastric cancer by sub-site and histologic type. Int J Cancer 1999; 83 : 223-9.  Back to cited text no. 61
    
62.
Gajalakshmi CK, Shanta V. Lifestyle and risk of stomach cancer: A hospital-based case-control study. Int J Epidemiol 1996; 25 : 1146-53.  Back to cited text no. 62
    
63.
Araghi M, Galanti MR, Lundberg M, Liu Z, Ye W, Lager A, et al. Smokeless tobacco (snus) use and colorectal cancer incidence and survival: Results from nine pooled cohorts. Scand J Public Health 2017; 45 : 741-8.  Back to cited text no. 63
    
64.
Nordenvall C, Nilsson PJ, Ye W, Nyrén O. Smoking, snus use and risk of right- and left-sided colon, rectal and anal cancer: A 37-year follow-up study. Int J Cancer 2011; 128 : 157-65.  Back to cited text no. 64
    
65.
Aithal RR, Shetty RS, Binu VS, Mallya SD, Shenoy KR, Nair S. Colorectal cancer and its risk factors among patients attending a tertiary care hospital in Southern Karnataka, India. Asian J Pharm Clin Res 2017; 10 : 109.  Back to cited text no. 65
    
66.
Hassan MM, Abbruzzese JL, Bondy ML, Wolff RA, Vauthey JN, Pisters PW, et al. Passive smoking and the use of noncigarette tobacco products in association with risk for pancreatic cancer: A case-control study. Cancer 2007; 109 : 2547-56.  Back to cited text no. 66
    
67.
Alguacil J, Silverman DT. Smokeless and other noncigarette tobacco use and pancreatic cancer: A case-control study based on direct interviews. Cancer Epidemiol Biomarkers Prev 2004; 13 : 55-8.  Back to cited text no. 67
    
68.
Ihsan R, Chauhan PS, Mishra AK, Yadav DS, Kaushal M, Sharma JD, et al. Multiple analytical approaches reveal distinct gene-environment interactions in smokers and non smokers in lung cancer. PLoS One 2011; 6 : e29431.  Back to cited text no. 68
    
69.
Ganesh B, Sushama S, Monika S, Suvarna P. A case-control study of risk factors for lung cancer in Mumbai, India. Asian Pac J Cancer Prev 2011; 12 : 357-62.  Back to cited text no. 69
    
70.
Gajalakshmi V, Hung RJ, Mathew A, Varghese C, Brennan P, Boffetta P, et al. Tobacco smoking and chewing, alcohol drinking and lung cancer risk among men in Southern India. Int J Cancer 2003; 107 : 441-7.  Back to cited text no. 70
    
71.
Rajbongshi N, Mahanta LB, Nath DC. Evaluation of female breast cancer risk among the betel quid chewer: A bio-statistical assessment in Assam, India. Nepal J Epidemiol 2015; 5 : 494-8.  Back to cited text no. 71
    
72.
Spangler JG, Michielutte R, Bell RA, Dignan MB. Association between smokeless tobacco use and breast cancer among native-American women in North Carolina. Ethn Dis 2001; 11 : 36-43.  Back to cited text no. 72
    
73.
Rajkumar T, Franceschi S, Vaccarella S, Gajalakshmi V, Sharmila A, Snijders PJ, et al. Role of paan chewing and dietary habits in cervical carcinoma in Chennai, India. Br J Cancer 2003; 88 : 1388-93.  Back to cited text no. 73
    
74.
Balasubramaniam G, Saoba S, Sarade M, Pinjare S. Case-control study of risk factors for non-Hodgkin lymphoma in Mumbai, India. Asian Pac J Cancer Prev 2013; 14 : 775-80.  Back to cited text no. 74
    
75.
Hartge P, Hoover R, Kantor A. Bladder cancer risk and pipes, cigars, and smokeless tobacco. Cancer 1985; 55 : 901-6.  Back to cited text no. 75
    
76.
Hayes RB, Pottern LM, Swanson GM, Liff JM, Schoenberg JB, Greenberg RS, et al. Tobacco use and prostate cancer in blacks and whites in the United States. Cancer Causes Control 1994; 5 : 221-6.  Back to cited text no. 76
    
77.
Zhou J, Michaud DS, Langevin SM, McClean MD, Eliot M, Kelsey KT, et al. Smokeless tobacco and risk of head and neck cancer: Evidence from a case-control study in New England. Int J Cancer 2013; 132 : 1911-7.  Back to cited text no. 77
    
78.
Bile KM, Shaikh JA, Afridi HUR, Khan Y. Smokeless tobacco use in Pakistan and its association with oropharyngeal cancer. East Mediterr Health J 2010; 16 : S24-30.  Back to cited text no. 78
    
79.
Lewin F, Norell SE, Johansson H, Gustavsson P, Wennerberg J, Biörklund A, et al. Smoking tobacco, oral snuff, and alcohol in the etiology of squamous cell carcinoma of the head and neck: A population-based case-referent study in Sweden. Cancer 1998; 82 : 1367-75.  Back to cited text no. 79
    
80.
Gupta PC, Pednekar MS, Parkin DM, Sankaranarayanan R. Tobacco associated mortality in Mumbai (Bombay) India. Results of the bombay cohort study. Int J Epidemiol 2005; 34 : 1395-402.  Back to cited text no. 80
    
81.
Henley SJ, Thun MJ, Connell C, Calle EE. Two large prospective studies of mortality among men who use snuff or chewing tobacco (United States). Cancer Causes Control 2005; 16 : 347-58.  Back to cited text no. 81
    
82.
Roosaar A, Johansson AL, Sandborgh-Englund G, Axéll T, Nyrén O. Cancer and mortality among users and nonusers of snus. Int J Cancer 2008; 123 : 168-73.  Back to cited text no. 82
    
83.
Timberlake DS, Nikitin D, Johnson NJ, Altekruse SF. A longitudinal study of smokeless tobacco use and mortality in the United States. Int J Cancer 2017; 141 : 264-70.  Back to cited text no. 83
    
84.
Gajalakshmi V, Kanimozhi V. Tobacco chewing and adult mortality: A case-control analysis of 22,000 cases and 429,000 controls, never smoking tobacco and never drinking alcohol, in South India. Asian Pac J Cancer Prev 2015; 16 : 1201-6.  Back to cited text no. 84
    
85.
Chao A, Thun MJ, Henley SJ, Jacobs EJ, McCullough ML, Calle EE, et al. Cigarette smoking, use of other tobacco products and stomach cancer mortality in US adults: The cancer prevention study II. Int J Cancer 2002; 101 : 380-9.  Back to cited text no. 85
    
86.
Accortt NA, Waterbor JW, Beall C, Howard G. Chronic disease mortality in a cohort of smokeless tobacco users. Am J Epidemiol 2002; 156 : 730-7.  Back to cited text no. 86
    
87.
Hsing AW, McLaughlin JK, Schuman LM, Bjelke E, Gridley G, Wacholder S, et al. Diet, tobacco use, and fatal prostate cancer: Results from the Lutheran brotherhood cohort study. Cancer Res 1990; 50 : 6836-40.  Back to cited text no. 87
    
88.
Cullen JW, Blot W, Henningfield J, Boyd G, Mecklenburg R, Massey MM, et al. Health consequences of using smokeless tobacco: Summary of the advisory committee's report to the surgeon general. Public Health Rep 1986; 101 : 355-73.  Back to cited text no. 88
    
89.
Sinha DN, Suliankatchi RA, Gupta PC, Thamarangsi T, Agarwal N, Parascandola M, et al. Global burden of all-cause and cause-specific mortality due to smokeless tobacco use: Systematic review and meta-analysis. Tob Control 2018; 27 : 35-42.  Back to cited text no. 89
    
90.
Gupta PC, Arora M, Sinha DN, Asma S, Parascandola M, editors. Smokeless tobacco and public health in India. New Delhi: Ministry of Health & Family Welfare, Government of India; 2016.  Back to cited text no. 90
    
91.
Brunnemann KD, Prokopczyk B, Djordjevic MV, Hoffmann D. Formation and analysis of tobacco-specific N-nitrosamines. Crit Rev Toxicol 1996; 26 : 121-37.  Back to cited text no. 91
    
92.
Khan Z, Tönnies J, Müller S. Smokeless tobacco and oral cancer in South Asia: A systematic review with meta-analysis. J Cancer Epidemiol 2014; 2014 : 1-11.  Back to cited text no. 92
    
93.
Wyss AB, Hashibe M, Lee YA, Chuang SC, Muscat J, Chen C, et al. Smokeless tobacco use and the risk of head and neck cancer: Pooled analysis of US studies in the INHANCE consortium. Am J Epidemiol 2016; 184 : 703-16.  Back to cited text no. 93
    
94.
Gupta B, Johnson NW. Systematic review and meta-analysis of association of smokeless tobacco and of betel quid without tobacco with incidence of oral cancer in South Asia and the Pacific. PLoS One 2014; 9 : e113385.  Back to cited text no. 94
    
95.
Gupta B, Bray F, Kumar N, Johnson NW. Associations between oral hygiene habits, diet, tobacco and alcohol and risk of oral cancer: A case-control study from India. Cancer Epidemiol 2017; 51 : 7-14.  Back to cited text no. 95
    
96.
Bhawna G. Burden of smoked and smokeless tobacco consumption in India – Results from the global adult tobacco survey India (GATS-India)- 2009-201. Asian Pac J Cancer Prev 2013; 14 : 3323-9.  Back to cited text no. 96
    
97.
National Cancer Institute and Centers for Disease Control and Prevention. Smokeless tobacco and public health: A global perspective. NIH publication No. 14-7983. Bethesda, MD: U.S. Department of Health and Human Services, Centers for Disease Control and Prevention and National Institutes of Health, National Cancer Institute; 2014. p. B5-63.  Back to cited text no. 97
    
98.
WHO Study Group on Tobacco Product Regulation: Report on the Scientific Basis of Tobacco Product Regulation: Third Report of a WHO Study Group. (WHO Technical Report Series; No. 955). Available from: http://www.who.int/tobacco/global_interaction/tobreg/publications/tsr_955/en/, accessed on March 5, 2018.  Back to cited text no. 98
    
99.
Bhisey RA. Chemistry and toxicology of smokeless tobacco. Indian J Cancer 2012; 49 : 364-72.  Back to cited text no. 99
    
100.
Idris AM, Nair J, Friesen M, Ohshima H, Brouet I, Faustman EM, et al. Carcinogenic tobacco-specific nitrosamines are present at unusually high levels in the saliva of oral snuff users in Sudan. Carcinogenesis 1992;13 : 1001-5.  Back to cited text no. 100
    
101.
Stich HF, Parida BB, Brunnemann KD. Localized formation of micronuclei in the oral mucosa and tobacco-specific nitrosamines in the saliva of “reverse” smokers, Khaini-tobacco chewers and gudakhu users. Int J Cancer 1992;50 : 172-6.  Back to cited text no. 101
    
102.
Bhide SV, Kulkarni J, Nair UJ, Spiegelhalder B, Preussmann R. Mutagenicity and carcinogenicity of masheri, a pyrolysed tobacco product, and its content of tobacco-specific nitrosamines. IARC Sci Publ 1987; 84 : 460-2.  Back to cited text no. 102
    
103.
Das RK, Dash BC. Genotoxicity of ‘gudakhu’, a tobacco preparation. II. In habitual users. Food Chem Toxicol 1992; 30 : 1045-9.  Back to cited text no. 103
    
104.
Herrero R, Castellsagué X, Pawlita M, Lissowska J, Kee F, Balaram P, et al. Human papillomavirus and oral cancer: The international agency for research on cancer multicenter study. J Natl Cancer Inst 2003; 95 : 1772-83.  Back to cited text no. 104
    
105.
Rivenson A, Hoffmann D, Prokopczyk B, Amin S, Hecht SS. Induction of lung and exocrine pancreas tumors in F344 rats by tobacco-specific and areca-derived N-nitrosamines. Cancer Res 1988; 48 : 6912-7.  Back to cited text no. 105
    
106.
Schuller HM. Mechanisms of smoking-related lung and pancreatic adenocarcinoma development. Nat Rev Cancer 2002; 2 : 455-63.  Back to cited text no. 106
    
107.
Prokopczyk B, Hoffmann D, Bologna M, Cunningham AJ, Trushin N, Akerkar S, et al. Identification of tobacco-derived compounds in human pancreatic juice. Chem Res Toxicol 2002; 15 : 677-85.  Back to cited text no. 107
    
108.
Ramadas K, Sauvaget C, Thomas G, Fayette JM, Thara S, Sankaranarayanan R, et al. Effect of tobacco chewing, tobacco smoking and alcohol on all-cause and cancer mortality: A cohort study from Trivandrum, India. Cancer Epidemiol 2010; 34 : 405-12.  Back to cited text no. 108
    


    Figures

  [Figure 1]
 
 
    Tables

  [Table 1], [Table 2], [Table 3], [Table 4], [Table 5]


This article has been cited by
1 Cross-sectional study on tobacco advertising, promotion and sponsorship (TAPS) and violations of tobacco sale regulations in Myanmar: do these factors affect current tobacco use among Myanmar high school students?
Su Myat Cho,Yu Mon Saw,Nyi Nyi Latt,Thu Nandar Saw,Hein Htet,Moe Khaing,Thet Mon Than,Ei Mon Win,Zaw Zaw Aung,Tetsuyoshi Kariya,Eiko Yamamoto,Nobuyuki Hamajima
BMJ Open. 2020; 10(2): e031933
[Pubmed] | [DOI]
2 Association of smokeless tobacco and cerebrovascular accident: a systematic review and meta-analysis of global data
R Gupta,S Gupta,S Sharma,DN Sinha,R Mehrotra
Journal of Public Health. 2019;
[Pubmed] | [DOI]
3 Association of smokeless tobacco with oral cancer: A review of systematic reviews
Smita Asthana,Parul Vohra,Satyanarayana Labani
Tobacco Prevention & Cessation. 2019; 5(October)
[Pubmed] | [DOI]
4 Genetic susceptibility to nicotine and/or alcohol addiction: a systematic review
Isabel Legaz,M. D. Pérez-Cárceles,Irene de la Calle,Fuensanta Arjona,Miriam Roca,Pablo Cejudo,Aurelio Luna,Eduardo Osuna
Toxin Reviews. 2019; : 1
[Pubmed] | [DOI]
5 Chemistry, metabolism and pharmacology of carcinogenic alkaloids present in areca nut and factors affecting their concentration
Alpana K. Gupta,Sonam Tulsyan,Nisha Thakur,Vishwas Sharma,Dhirendra N. Sinha,Ravi Mehrotra
Regulatory Toxicology and Pharmacology. 2019; : 104548
[Pubmed] | [DOI]
6 Smokeless tobacco and oral cancer in the Middle East and North Africa: A systematic review and meta-analysis
Mir Faeq Quadri,Santosh Tadakamadla,Tenny John
Tobacco Induced Diseases. 2019; 17(July)
[Pubmed] | [DOI]
7 A review of the effects of tobacco smoking on cancer treatment: smoking cessation intervention should be integrated into the cancer care continuum
Rahil Kassim,Ernest Osei,Kelly A. Cronin
Journal of Radiotherapy in Practice. 2019; : 1
[Pubmed] | [DOI]



 

Top
 
 
  Search
 
    Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
    Access Statistics
    Email Alert *
    Add to My List *
* Registration required (free)  

 
  In this article
    Abstract
    Material & M...
   Results
   Discussion
    Conclusion &...
    References
    Article Figures
    Article Tables

 Article Access Statistics
    Viewed2319    
    Printed11    
    Emailed0    
    PDF Downloaded526    
    Comments [Add]    
    Cited by others 7    

Recommend this journal